A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), compared with 5.1 in (13 cm) with Wegovy. The "head-to-head results demonstrated tirzepatide [Zepbound] led to ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Lilly disclosed the initial weight loss results last December. Novo noted that Wegovy is approved to help prevent strokes and heart attacks, saying in a statement that “obesity is about more ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.